KPIs & Operating Metrics(New)

Balance Sheet

Cash Flow Statement

Acquisitions Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Change in Taxes Change in Taxes Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Dividends Paid - Common Dividends Paid - Common Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Preferred Shares Repurchased Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued Short-Term Debt issuances Short-Term Debt repayments

Daily Values

Growth Metrics

Biolife Solutions (BLFS) Amortization of Deferred Charges (2016 - 2023)

Biolife Solutions (BLFS) has disclosed Amortization of Deferred Charges for 8 consecutive years, with $13000.0 as the latest value for Q1 2023.

Quarterly Amortization of Deferred Charges changed N/A to $13000.0 in Q1 2023 from the year-ago period, while the trailing twelve-month figure was $13000.0 through Dec 2023, down 27.78% year-over-year, with the annual reading at $13000.0 for FY2023, 27.78% down from the prior year.
Amortization of Deferred Charges for Q1 2023 was $13000.0 at Biolife Solutions, down from $18000.0 in the prior quarter.
The five-year high for Amortization of Deferred Charges was $18000.0 in Q4 2022, with the low at $13000.0 in Q1 2023.